Type Public Industry Pharmaceuticals Founded 1998 | Traded as NASDAQ: PTCT Website ptcbio.com | |
 | ||
Stock price PTCT (NASDAQ) US$ 9.06 +0.22 (+2.49%)17 Mar, 4:00 PM GMT-4 - Disclaimer Headquarters South Plainfield, New Jersey, United States | ||
PTC Therapeutics is a US pharmaceutical company focused on the development of small molecule, orally administered treatments for orphan diseases.
Since 2003, PTC has been working on a drug for Duchenne muscular dystrophy.
In September 2009, PTC has entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases.
As of May 2016, PTC portfolio includes small-molecule compounds for treatment of spinal muscular atrophy (RG7800 and RG7916) and Duchenne muscular dystrophy (Ataluren and another exon skipping compound).
References
PTC Therapeutics Wikipedia(Text) CC BY-SA